HomeABBV • NYSE
add
AbbVie Inc
$186.79
Makalipas ang Oras ng Trabaho:(0.00%)0.00
$186.79
Sarado: Hun 26, 6:32:24 PM GMT-4 · USD · NYSE · Disclaimer
Nakaraang pagsara
$185.39
Sakop ng araw
$185.79 - $188.99
Sakop ng taon
$163.52 - $218.66
Market cap
329.95B USD
Average na Volume
5.78M
P/E ratio
79.65
Dividend yield
3.51%
Primary exchange
NYSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Kita | 13.34B | 8.39% |
Gastos sa pagpapatakbo | 5.28B | 8.44% |
Net na kita | 1.29B | -6.06% |
Net profit margin | 9.64 | -13.31% |
Kita sa bawat share | 2.46 | 6.49% |
EBITDA | 6.10B | 11.89% |
Aktuwal na % ng binabayarang buwis | 22.40% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 5.18B | -71.35% |
Kabuuang asset | 136.16B | -8.54% |
Kabuuang sagutin | 134.70B | -4.35% |
Kabuuang equity | 1.46B | — |
Natitirang share | 1.77B | — |
Presyo para makapag-book | 231.74 | — |
Return on assets | 7.48% | — |
Return on capital | 14.21% | — |
Cash Flow
Net change in cash
(USD) | Mar 2025info | Y/Y na pagbabago |
---|---|---|
Net na kita | 1.29B | -6.06% |
Cash mula sa mga operasyon | 1.64B | -59.53% |
Cash mula sa pag-invest | -735.00M | 92.33% |
Cash mula sa financing | -1.26B | -111.63% |
Net change in cash | -349.00M | -106.64% |
Malayang cash flow | 1.12B | -73.12% |
Tungkol
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Itinatag
Abr 10, 2012
Headquarters
Website
Mga Empleyado
55,000